ABCL
Price
$8.12
Change
+$0.74 (+10.03%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
2.48B
33 days until earnings call
Intraday BUY SELL Signals
RXRX
Price
$3.81
Change
+$0.14 (+3.80%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
2.02B
38 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABCL vs RXRX

ABCL vs RXRX Comparison Chart in %
View a ticker or compare two or three
VS
ABCL vs. RXRX commentary
Jul 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Buy and RXRX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2026
Stock price -- (ABCL: $7.38 vs. RXRX: $3.52)
Brand notoriety: ABCL and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 168% vs. RXRX: 206%
Market capitalization -- ABCL: $2.48B vs. RXRX: $2.02B
ABCL [@Biotechnology] is valued at $2.48B. RXRX’s [@Biotechnology] market capitalization is $2.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $134.02B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, both ABCL and RXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 5 TA indicator(s) are bullish while RXRX’s TA Score has 5 bullish TA indicator(s).

  • ABCL’s TA Score: 5 bullish, 4 bearish.
  • RXRX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ABCL is a better buy in the short-term than RXRX.

Price Growth

ABCL (@Biotechnology) experienced а +10.81% price change this week, while RXRX (@Biotechnology) price change was +5.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.30%. For the same industry, the average monthly price growth was +5.93%, and the average quarterly price growth was +1921.84%.

Reported Earning Dates

ABCL is expected to report earnings on Aug 06, 2026.

RXRX is expected to report earnings on Aug 11, 2026.

Industries' Descriptions

@Biotechnology (+2.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($2.48B) has a higher market cap than RXRX($2.02B). ABCL YTD gains are higher at: 115.789 vs. RXRX (-13.936). ABCL has higher annual earnings (EBITDA): -167.02M vs. RXRX (-478.66M). RXRX has more cash in the bank: 654M vs. ABCL (505M). RXRX has less debt than ABCL: RXRX (72.4M) vs ABCL (140M). ABCL has higher revenues than RXRX: ABCL (79.2M) vs RXRX (65.7M).
ABCLRXRXABCL / RXRX
Capitalization2.48B2.02B123%
EBITDA-167.02M-478.66M35%
Gain YTD115.789-13.936-831%
P/E RatioN/AN/A-
Revenue79.2M65.7M121%
Total Cash505M654M77%
Total Debt140M72.4M193%
TECHNICAL ANALYSIS
Technical Analysis
ABCLRXRX
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
83%
MACD
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 9 days ago
80%
Bullish Trend 9 days ago
83%
Declines
ODDS (%)
Bearish Trend 25 days ago
82%
Bearish Trend 12 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 4 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
ABCL
Daily Signal:
Gain/Loss:
RXRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TPLC50.580.32
+0.64%
Timothy Plan US Large/Mid Cap Core ETF
TIPX18.740.02
+0.11%
State Street® SPDR® Blmbg 1-10 YrTIPSETF
AQLT31.390.02
+0.06%
iShares MSCI Global Quality Factor ETF
MTRA27.55N/A
N/A
Invesco International Growth Focus ETF
FLAX35.69-0.59
-1.62%
Franklin FTSE Asia ex Japan ETF

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with RXRX. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
N/A
RXRX - ABCL
60%
Loosely correlated
N/A
PRME - ABCL
57%
Loosely correlated
N/A
CRSP - ABCL
56%
Loosely correlated
N/A
VCYT - ABCL
56%
Loosely correlated
N/A
ABSI - ABCL
54%
Loosely correlated
N/A
More